GLP-1 rapid rollout

Hims & Hers, 2024

In May 2024, Hims & Hers moved quickly to launch compounded GLP-1 access as semaglutide shortages created a narrow market window. I led rapid concepting sessions to drive cross-functional alignment across marketing, compliance, legal, and engineering, making key design calls under tight regulatory constraints to get from zero to launched in three weeks. The launch contributed to a 30% increase in stock price. Full case study available on request.

Company

Hims & Hers

Deliverables

Discovery, user research, requirements, testing

Date

June 2024

With a narrow market window and a three-week timeline, I led rapid concepting to align stakeholders across design, engineering, compliance, legal, and marketing. My focus was on identifying the minimum viable experience without compromising quality, scoping fast follows clearly so the team could move without second-guessing trade-offs, and keeping leadership aligned through the process. The product launched nationally across all states.